Details for New Drug Application (NDA): 012157
✉ Email this page to a colleague
NDA 012157 describes NORFLEX, which is a drug marketed by Pai Holdings Pharm and Bausch and is included in two NDAs. Additional details are available on the NORFLEX profile page.
The generic ingredient in NORFLEX is orphenadrine citrate. There are nine drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the orphenadrine citrate profile page.
The generic ingredient in NORFLEX is orphenadrine citrate. There are nine drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the orphenadrine citrate profile page.
Summary for 012157
| Tradename: | NORFLEX |
| Applicant: | Bausch |
| Ingredient: | orphenadrine citrate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
